UCB has announced that the European Commission (EC) has approved expanding the use of its anti-epileptic drug (AED) Vimpat (lacosamide) as monotherapy and adjunctive therapy in the treatment of partial-onset
Tag "CHMP"
![EMA’s CHMP backs Novartis’ Zykadia for first-line use in lung cancer](http://www.biopharmabusiness.com/wp-content/uploads/2017/05/novartis-hq-basel-505x306_c.jpg)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval to expand the use of Novartis’ Zykadia (ceritinib) in anaplastic lymphoma kinase (ALK)-positive non-small cell